NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease

Part of paid clinical trials in Bradenton, Florida.

Sponsor
Agomab Spain S.L.U.
Study ID
NCT07683325
Phase
PHASE2
Status
Recruiting

Conditions

  • Fibrostenotic Crohn's Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ontunisertib — DRUG
    Oral capsule
  • Ontunisertib — DRUG
    Oral capsule
  • Ontunisertib — DRUG
    Oral capsule
  • Placebo — DRUG
    Matching oral capsule

Study Details

Many patients with Crohn's disease (CD) develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals. Because of these symptoms, patients often require bowel resection surgery. The objective of this clinical trial is to evaluate the efficacy, safety, and dose-response relationship of ontunisertib in participants with CD and symptomatic strictures, and contribute to the validation of novel endpoints to assess potential treatment benefit in patients with fibrostenosing Crohn's disease (FSCD). The participants will be in the trial for a duration of up to 60 weeks, consisting of a 6-week screening period (with 2 screening visits), a 52-week treatment period, and a 2-week follow-up period. The visit frequency in the treatment period will be every 6 to 8 weeks.

Key Dates

First listed
Jul 6, 2026
Start date
Oct 30, 2026
Status verified
Aug 2026
Primary completion
Dec 31, 2028
Completion
Jun 30, 2029

Study Design

Enrollment
320 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Ontunisertib High
    Ontunisertib high dose
  • Experimental: Ontunisertib Medium
    Ontunisertib medium dose
  • Experimental: Ontunisertib Low
    Ontunisertib low dose
  • Experimental: Placebo
    Matching placebo

Primary Outcome Measure

Proportion of participants achieving endoscopic passability of the ileal index stricture [ Time Frame: At week 24 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Synergy Healthcare, LLCBradentonFlorida34209-

Find similar trials in Bradenton, FL